Atrial Fibrillation Market Grows with Aging Population and Innovation in Ablation & Anticoagulants | AdvaCare Pharma, Sanofi, Pfizer Inc. Teva Pharmaceuticals USA, Inc., Glenmark Pharmaceuticals Inc.

The Global Atrial Fibrillation Market reached US$ 26.75 billion in 2024 and is expected to reach US$ 63.79 billion by 2033, growing at a CAGR of 10.6 % during the forecast period 2025-2033.

Atrial Fibrillation Market Report by DataM Intelligence offers a detailed assessment of the global pharmaceutical and healthcare landscape, highlighting market size, key players, and critical growth drivers. With a focus on novel oral anticoagulants (NOACs), catheter ablation technologies, and aging populations, the report delivers strategic insights to support stakeholders navigating the cardiovascular care segment from 2025 to 2033.

Download exclusive insights with our detailed sample report (Corporate Email ID gets priority access): https://www.datamintelligence.com/download-sample/atrial-fibrillation-market?ophp

Atrial Fibrillation (AFib) is an irregular, often rapid heartbeat that can lead to stroke and heart failure. The treatment market is expanding due to the rising prevalence of cardiovascular diseases and aging populations. Key growth drivers include anticoagulants, catheter ablation technologies, and digital ECG monitoring systems.

Atrial Fibrillation Market Competitors Overview:

AdvaCare Pharma, Sanofi, Pfizer Inc. Teva Pharmaceuticals USA, Inc., Glenmark Pharmaceuticals Inc., GSK plc., Boehringer Ingelheim Pharmaceuticals, Inc., Bayer AG, DAIICHI SANKYO COMPANY, LIMITED., AstraZeneca, Johnson & Johnson, Boston Scientific Corporation, Medtronic, and Abbott. among others.

Important Industry Updates of 2025:

✅ In February 11, 2025 - Novartis announced its acquisition of Anthos Therapeutics from Blackstone Life Sciences in a deal valued up to $3.08 billion, comprising $925 million upfront and up to $2.15 billion in milestone-based payments. The acquisition centers around abelacimab, Anthos' investigational anticoagulant targeting Factor XI/XIa, aimed at reducing stroke risk in atrial fibrillation with minimal bleeding complications.

✅ In 2025 - Asundexian, a Factor XIa inhibitor developed by Bayer, continued its evaluation in atrial fibrillation through the PACIFIC-AF and OCEANIC-AF trials, comparing its safety and efficacy to apixaban. Although the OCEANIC-AF trial was terminated early due to thromboembolic risk concerns, the drug showed promising bleeding risk reduction. Development remains ongoing in other patient populations, with updated data expected through 2026.

Methodology and Scope

The Atrial Fibrillation Market Report is built on a rigorous research methodology that integrates primary interviews, expert insights, and validated secondary data from company reports, industry publications, and reliable databases. Utilizing both bottom-up and top-down approaches, the analysis ensures high data accuracy through triangulation. The report covers current market dynamics, growth opportunities, and key strategic developments across global and regional markets.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/atrial-fibrillation-market?ophp

Atrial Fibrillation Market Segments Overview:

∎ By Treatment Type (Pharmacological Treatment, Non-Pharmacological Treatment)
∎ By End-User (Hospitals & Specialty Clinics, Ambulatory Surgical Centers, Others)

The novel oral anticoagulants (NOACs) segment is expected to lead, as drugs like apixaban and rivaroxaban offer superior safety and convenience over traditional therapies like warfarin.

Regional Overview for Atrial Fibrillation Market:

⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

North America dominates the atrial fibrillation market, supported by technological advancements in ablation procedures and high diagnosis rates. Asia Pacific is emerging as the fastest growing region due to its aging population and rising awareness of hea

Looking for in-depth insights? Grab the full report: https://www.datamintelligence.com/buy-now-page?report=atrial-fibrillation-market?ophp

The Report Covers:

➡ In-depth analysis of the demand-supply gap, market size estimates, SWOT and PESTEL analysis, along with global market forecasts.
➡ Strategic recommendations with a focused go-to-market approach.
➡ An unbiased evaluation of overall market performance.
➡ Region- and country-specific insights, with customized reports available upon request.
➡ Identification of high-potential and niche segments and regions demonstrating strong growth prospects.

People Also Ask:

➤ What are the current global trends in sales, production, imports, and exports within the Atrial Fibrillation market?
➤ Who are the leading manufacturers, and what are their production volumes, pricing strategies, and revenue metrics?
➤ What are the major opportunities and challenges facing vendors in this market?
➤ Which product categories, applications, or end-user segments are contributing most to market growth and share?
➤ What are the primary factors driving and restraining growth in the Atrial Fibrillation market?

Unlock 360° Market Intelligence with 2 Days FREE Trial Access of DataM Subscription Now!: https://www.datamintelligence.com/reports-subscription?ophp

✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Pipeline Analysis For Drugs Discovery
✅ Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Competitive Landscape

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.